What is the indication for aspirin use following CABG surgery?

Aspirin is widely indicated following coronary artery bypass graft (CABG) surgery primarily for its role in secondary prevention of cardiovascular events. This use is grounded in its antiplatelet properties, which help in reducing the likelihood of thrombus formation on the newly grafted arteries and other coronary lumens. After CABG, patients remain at risk for ischemic events due to atherosclerosis potentially affecting other coronary arteries, and aspirin helps mitigate these risks by inhibiting platelet aggregation.

This indication aligns with guidelines that recommend aspirin therapy to improve outcomes in patients who have undergone cardiac surgery, as it has been proven to decrease the incidence of myocardial infarction and the need for repeat revascularization procedures. The ability of aspirin to improve graft patency by preventing clot formation on the grafts is crucial for the long-term success of the surgery.

In contrast, other options presented do not accurately reflect the recognized role of aspirin in post-CABG care. Aspirin is not contraindicated due to bleeding risks; in fact, it is routinely used because the benefits of preventing thrombotic complications generally outweigh the existing bleeding risks in most patients. While it's true that aspirin use is beneficial for all CABG patients, suggesting it's limited to only those with arterial grafts